Abbott Laboratories' new Absorb bioresorbable stent has already moved to market in Europe, Asia and South America, and the first U.S. placement of the stent was done last month at North Mississippi Medical Center, one of 200 hospitals collecting data as part of a clinical trial. The Mayo Clinic and Cleveland Clinic are among the hospitals testing the device, and Abbott hopes to seek government approval for U.S. use in 2015.

Related Summaries